Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses

BACKGROUND: Our study investigated the rate of breakthrough SARS-CoV-2 infection and clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the anti-CD20 monoclonal antibody (Ab), ocrelizumab, before first, second and third BNT162b2 mRNA vaccinations. To correlate cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Novak, Frederik, Bajwa, Hamza Mahmood, Coia, John Eugenio, Nilsson, Anna Christine, Nielsen, Christian, Holm, Dorte K, Østergaard, Kamilla, Hvidt, Mathilde Vilhelmine Miller, Byg, Keld-Erik, Johansen, Isik S, Mittl, Kristen, Rowles, William, Zamvil, Scott S, Bove, Riley, Sabatino, Joseph J, Sejbaek, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579504/
https://www.ncbi.nlm.nih.gov/pubmed/37185261
http://dx.doi.org/10.1136/jnnp-2022-330757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579504/
https://www.ncbi.nlm.nih.gov/pubmed/37185261
http://dx.doi.org/10.1136/jnnp-2022-330757

Ejemplares similares